A detailed history of Tower Research Capital LLC (Trc) transactions in Anebulo Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,694 shares of ANEB stock, worth $3,933. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,694
Previous 3,300 18.36%
Holding current value
$3,933
Previous $9,000 44.44%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.77 - $3.08 $1,072 - $1,866
-606 Reduced 18.36%
2,694 $5,000
Q2 2024

Aug 13, 2024

SELL
$1.9 - $3.12 $3,492 - $5,734
-1,838 Reduced 35.77%
3,300 $9,000
Q1 2024

May 15, 2024

SELL
$2.34 - $3.0 $9,275 - $11,892
-3,964 Reduced 43.55%
5,138 $14,000
Q4 2023

Feb 13, 2024

SELL
$1.71 - $3.17 $20,090 - $37,244
-11,749 Reduced 56.35%
9,102 $22,000
Q3 2023

Nov 14, 2023

BUY
$2.15 - $3.49 $31,712 - $51,477
14,750 Added 241.76%
20,851 $63,000
Q2 2023

Aug 14, 2023

BUY
$2.06 - $2.98 $2,047 - $2,962
994 Added 19.46%
6,101 $14,000
Q1 2023

May 09, 2023

BUY
$2.27 - $3.25 $3,427 - $4,907
1,510 Added 41.98%
5,107 $15,000
Q4 2022

Feb 10, 2023

SELL
$1.79 - $3.39 $6,682 - $12,654
-3,733 Reduced 50.93%
3,597 $9,000
Q3 2022

Nov 10, 2022

BUY
$2.8 - $5.49 $529 - $1,037
189 Added 2.65%
7,330 $21,000
Q2 2022

Aug 15, 2022

BUY
$2.7 - $7.15 $17,239 - $45,652
6,385 Added 844.58%
7,141 $37,000
Q1 2022

May 12, 2022

BUY
$6.0 - $7.7 $4,536 - $5,821
756 New
756 $5,000
Q4 2021

Feb 14, 2022

SELL
$5.84 - $7.3 $227 - $284
-39 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$6.55 - $7.77 $779 - $924
-119 Reduced 75.32%
39 $0
Q2 2021

Aug 16, 2021

BUY
$6.58 - $8.95 $1,039 - $1,414
158 New
158 $1,000

Others Institutions Holding ANEB

About Anebulo Pharmaceuticals, Inc.


  • Ticker ANEB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,633,200
  • Market Cap $37.4M
  • Description
  • Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The ...
More about ANEB
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.